Radiotherapy with concurrent docetaxel and carboplatin for head and neck cancer

Kumiko Karasawa, H. Shinoda, K. Katsui, K. Seki, M. Kohno, N. Hanyu, S. Nasu, H. Muramatsu, K. Maebayashi, N. Mitsuhashi, T. Yoshihara

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: This study was designed to evaluate the concomitant use of docetaxel and carboplatin for radiosensitization in head and neck cancer. Materials and Methods: One dose of docetaxel at 10 mg/m2 and five doses of carboplatin at AUC of 0.4 per week were administered to patients during the first two weeks of radiotherapy. Sixteen patients were treated with this regimen. Radiotherapy was given to a total dose of 64.8 to 82.0 Gy. Altered fractionation radiotherapy was performed in 12 patients with untreated advanced tumors. Results: The complete response (CR) rate was 81%, with a partial response (PR) rate of 19%. Toxicities included grade 3 mucositis in 69% of patients and grade 2 dermatitis in 56% of patients. Conclusion: This schedule of docetaxel and carboplatin combined with radiotherapy may become a useful approach for the management of head and neck cancer with proper management of mucositis.

Original languageEnglish
Pages (from-to)3785-3788
Number of pages4
JournalAnticancer research
Volume22
Issue number6 B
Publication statusPublished - Nov 1 2002
Externally publishedYes

Keywords

  • Chemoradiotherapy
  • Concurrrent chemotherapy
  • Docetaxel
  • Head and neck cancer
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Radiotherapy with concurrent docetaxel and carboplatin for head and neck cancer'. Together they form a unique fingerprint.

  • Cite this

    Karasawa, K., Shinoda, H., Katsui, K., Seki, K., Kohno, M., Hanyu, N., Nasu, S., Muramatsu, H., Maebayashi, K., Mitsuhashi, N., & Yoshihara, T. (2002). Radiotherapy with concurrent docetaxel and carboplatin for head and neck cancer. Anticancer research, 22(6 B), 3785-3788.